Healthpeak Properties (DOC) reported third-quarter FFO as Adjusted of $0.44 per share. That beat the $0.43 consensus by a penny but fell short of the $0.45 Earnings Whisper number, a 2.2% miss against the higher bar. Earnings fell 4.3% from a year ago. Revenue of $820.89 million rose 16.3% and topped the $758.25 million consensus by 8.3%. Management also raised full-year FFO as Adjusted guidance to $1.76-$1.78 from $1.73-$1.77, though the new range remains in line with estimates. The central tension is that the operating story is clearly improving while per-share earnings keep drifting lower.
The revenue beat deserves scrutiny. Nearly all of the growth came from resident fees and services, which climbed to $268.3 million from $150.5 million as majority-owned Janus Living consolidated a wave of senior housing acquisitions. Rental and related revenues, the core of the outpatient medical and lab business, grew only about 1% to $545.4 million. That senior housing growth is also shared: roughly 31% of Janus belongs to outside holders, and the noncontrolling interests' share of earnings rose to $19.4 million from $7.3 million. Meanwhile, interest expense increased to $83.9 million from $76.8 million, and the Brookfield outpatient joint venture recapitalization handed away 49% of an 86-property portfolio's income. The result was quarterly FFO as Adjusted of $0.44, down from $0.45 in Q1 and $0.46 in Q2. On a GAAP basis, Healthpeak swung to net income of $0.02 per share from a $0.17 loss a year ago, when it took joint venture impairments. GAAP EPS guidance, however, was cut to $0.39-$0.41 because of depreciation tied to the Janus acquisitions, which does not affect FFO.
Beneath the headline, the call delivered the most constructive lab commentary in some time. Q3 lab leasing reached 480,000 square feet, up from 381,000 in Q2 and 141,000 in Q1. Another 643,000 square feet has been executed or placed under letter of intent since quarter end. Lab occupancy rose 130 basis points sequentially to 79.8%, up 270 basis points year to date and well ahead of management's earlier target. Torrey Pines is now fully leased, compared with roughly 65% six months ago, with multiple tenants bidding for the same suites. Management also cited AI- and robotics-adjacent demand absorbing space. Senior housing same-store NOI growth accelerated to 25.9% from 19% in Q2, and outpatient retention improved to 81.7%. Guidance for every same-store segment moved higher, and the total same-store range rose 50 basis points to 0.5%-2.0%. The tone shifted from cautious to openly confident.
That confidence is now backed by capital. Healthpeak is buying three partially vacant life science buildings adjacent to existing campuses. They are about 41% occupied, with an in-place cash yield near 5% and a targeted stabilized yield of 9-10%. Management said roughly $1 billion of lab acquisitions has closed or is in the pipeline. The trade-off is that reported lab occupancy will optically reset lower as these deals close, and lease-up is expected to take two to three years, including 12-15 month build-outs. Outpatient quarterly leasing slowed to 846,000 square feet from 1.2 million, and total occupancy slipped to 90.3% on the recap and asset sales. Lab renewal rents also rolled down 5.6%, though on a small sample.
The bigger issue for bears is 2027. Healthpeak faces $1.4 billion of maturities next year, about $1.1 billion of it in the first quarter, carrying roughly 3% coupons with the 10-year Treasury near 5%. The release disclosed a new $500 million delayed-draw term loan at SOFR plus 80 basis points. The call referenced about $900 million of delayed-draw capacity aimed at those maturities. Even so, the raised guidance implies Q4 FFO near $0.42, a $1.68 annualized run rate, and consensus implies little earnings growth in 2027. Management expects outpatient internal growth to accelerate as expirations decline, but higher financing costs and a diluted income base are likely to absorb much of that improvement.
Investors have been leaning skeptical. Sentiment remained negative and weakened modestly, moving from -0.22 to -0.28. Shares have fallen 11.5% since the $22.00 open following the August report and now trade at $19.48, just 1.8% above the 200-day moving average of $19.13. The Earnings Whispers trend readings are mixed, with momentum positive but AVWAP negative.
The bottom line is that Healthpeak's quarter strengthened the fundamental narrative while leaving the earnings trajectory unresolved. Lab demand is inflecting, senior housing is compounding, and guidance has now been raised three times. Yet quarterly FFO continues to decline, the revenue beat came largely from a partially owned subsidiary, and 2027 refinancing threatens to offset operating gains. Investors need evidence that leasing momentum can outrun higher interest costs before the per-share story turns.